1. Home
  2. RYTM vs SON Comparison

RYTM vs SON Comparison

Compare RYTM & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • SON
  • Stock Information
  • Founded
  • RYTM 2008
  • SON 1899
  • Country
  • RYTM United States
  • SON United States
  • Employees
  • RYTM N/A
  • SON 28000
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • SON Containers/Packaging
  • Sector
  • RYTM Health Care
  • SON Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • SON Nasdaq
  • Market Cap
  • RYTM 4.3B
  • SON 4.4B
  • IPO Year
  • RYTM 2017
  • SON N/A
  • Fundamental
  • Price
  • RYTM $61.99
  • SON $43.05
  • Analyst Decision
  • RYTM Strong Buy
  • SON Strong Buy
  • Analyst Count
  • RYTM 12
  • SON 8
  • Target Price
  • RYTM $76.75
  • SON $56.25
  • AVG Volume (30 Days)
  • RYTM 525.0K
  • SON 591.4K
  • Earning Date
  • RYTM 08-05-2025
  • SON 07-30-2025
  • Dividend Yield
  • RYTM N/A
  • SON 4.91%
  • EPS Growth
  • RYTM N/A
  • SON N/A
  • EPS
  • RYTM N/A
  • SON 1.54
  • Revenue
  • RYTM $136,863,000.00
  • SON $5,705,957,000.00
  • Revenue This Year
  • RYTM $37.56
  • SON $45.00
  • Revenue Next Year
  • RYTM $74.99
  • SON $0.62
  • P/E Ratio
  • RYTM N/A
  • SON $28.02
  • Revenue Growth
  • RYTM 48.88
  • SON 13.66
  • 52 Week Low
  • RYTM $39.46
  • SON $39.46
  • 52 Week High
  • RYTM $69.89
  • SON $57.21
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 47.67
  • SON 38.14
  • Support Level
  • RYTM $60.70
  • SON $44.25
  • Resistance Level
  • RYTM $62.65
  • SON $46.35
  • Average True Range (ATR)
  • RYTM 2.39
  • SON 0.90
  • MACD
  • RYTM -0.52
  • SON -0.27
  • Stochastic Oscillator
  • RYTM 14.04
  • SON 0.30

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

Share on Social Networks: